Drug intelligence / Profile preview

xanthomicrol

Development stage
Preclinical
Modality
Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
Administration
Oral, Not Formally Established For Pharmaceutical Use
01

Overview

Xanthomicrol is a **plant-derived, trimethoxylated hydroxyflavone** with reported antineoplastic, antiangiogenic, anti-inflammatory, and antimicrobial activity. Mechanistic studies indicate that xanthomicrol induces cytotoxic and antiproliferative effects in malignant cell lines, selectively reducing cancer cell viability with minimal toxicity to normal cells. Its anticancer activities are due to modulation of lipid metabolism, induction of apoptosis, cell cycle arrest at G2/M phase, and inhibition of de novo lipogenesis. In vivo, xanthomicrol has been shown to inhibit tumor growth and angiogenesis, associated with downregulation of the PI3K/Akt pathway and suppression of HIF-1α and VEGF expression. Molecular modeling studies also suggest xanthomicrol may inhibit DNA methyltransferase 1 (DNMT1), similar to decitabine, suggesting potential epigenetic effects[1][2][3][4][5][6].

Other names
4',5-dihydroxy-6,7,8-trimethoxyflavone4H-1-benzopyran-4-one, 5-hydroxy-2-(4-hydroxyphenyl)-6,7,8-trimethoxy-5-hydroxy-2-(4-hydroxyphenyl)-6,7,8-trimethoxychromen-4-one
02

Targets

CCND1 (Cyclin D1)AKT1 (Proto-oncogene serine/threonine-protein kinase Akt1)DNMT1 (DNA (cytosine-5)-methyltransferase 1)

Beyond the preview

Go deeper on xanthomicrol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on xanthomicrol.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call